SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: molemania who wrote (305)12/16/1997 1:05:00 PM
From: NeuroInvestment  Read Replies (3) of 675
 
While I would have preferred to be wrong, in the October 97 issue of NI I wrote:"we see no reason to expect positive news from the full analysis of the halted stroke study (news due late 4Q). Unfortunately, this signals the death knell for Cerestat as a neuroprotectant."

So there was no surprise in today's news.It would have been a shock to hear otherwise. CN and BI will be sifting through the wreckage to see if there are any subgroups of patients who did show improvement....they may find something, but I am not betting that it will be enough to cause BI to fund another Phase III. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News